Details of the Drug Reposition

General Information of This Drug (ID: DMNDHKL)

Drug Name
TG-1701   DMNDHKL
Drug Type
Small molecular drug

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 1 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03671590) Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies. U.S. National Institutes of Health.